QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
📍World EPA 2026: Two productive days in Amsterdam
We have now completed two engaging days at the World Evidence, Pricing and Access Congress
The conversations have been thoughtful, forward-looking, and grounded in the realities of access across Europe.
AI in evidence generation, implementation of Joint Clinical Assessment JCA, and ongoing discussions around MFN continue to shape the agenda.
A sincere thank you to our colleagues from IGES Pharma. Working side by side as part of the […]
World EPA 2026: Day 1 complete
A full and energising first day at the World Evidence, Pricing and Access Congress in Amsterdam.
It was a pleasure to reconnect with long-standing connections, meet new ones, and continue conversations across the access community.
We are pleased to be here with our colleagues from IGES Pharma as part of the athagoras Group, and to have the support of our group leadership, […]
World EPA 2026: Meet us tomorrow
📆 Tomorrow (3 March), Béranger Lueza, PhD and Abraham Choong will be in Amsterdam for the World Evidence, Pricing and Access Congress.
📍 You will find us at booth 302, together with our colleagues from IGES Pharma as part of the athagoras Group.
If you would like to discuss RWE, HEOR, […]
Nordic RWD: an evidence ecosystem, not just data
We have now completed our journey across Denmark, Sweden, Finland and Norway.
Four countries.
Four distinct strengths.
One shared evidence philosophy.
Denmark – deeply integrated national registries and a strong epidemiological tradition
Sweden– clinically rich quality registries embedded in routine care
Finland – structured secondary-use frameworks and clear data governance pathways
Norway– longitudinal linkage across the full patient journey
What defines the Nordics is not scale alone.
It is:
➡️ Universal healthcare coverage
➡️ Personal identifiers enabling cross-sector linkage
➡️ Decades of registry […]